Flex Pharma Inc (FLKS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Flex Pharma Inc (FLKS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9355
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Flex Pharma Inc (Flex Pharma) is a clinical-stage biotechnology company that offers discovery and development of innovative and proprietary treatments for muscle cramps, spasms and spasticity connected to the severe neurological diseases of ALS, MS, fibromyalgia, hypomagnesemia, hypocalcemia, piriformis syndrome, lower lumbar radiculopathy, and peripheral neuropathy such as Charcot-Marie-Tooth (CMT). Flex Pharma also provides novel treatments for neurological conditions. The company’s lead drug compound, FLX-787, is in development under Fast Track designation for the treatment of severe muscle cramps associated with ALS. The company is developing FLX-787 for dysphagia, which involves difficulty in swallowing. Flex Pharma is headquartered in Boston, Massachusetts, the US.

Flex Pharma Inc (FLKS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Flex Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Flex Pharma Raises USD40 Million in Venture Financing 10
Flex Pharma Raises USD16 Million in Venture Financing 12
Equity Offering 13
Flex Pharma Raises USD86.4 Million in IPO 13
Flex Pharma Inc – Key Competitors 15
Flex Pharma Inc – Key Employees 16
Flex Pharma Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Financial Announcements 18
Aug 01, 2018: Flex Pharma Reports Second Quarter 2018 Financial Results 18
May 02, 2018: Flex Pharma Reports First Quarter 2018 Financial Results 19
Mar 07, 2018: Flex Pharma announces year end 2017 financial results 20
Nov 06, 2017: Flex Pharma Reports Third Quarter 2017 Financial Results 22
Aug 02, 2017: Flex Pharma Reports Second Quarter 2017 Financial Results 24
May 03, 2017: Flex Pharma Reports First Quarter 2017 Financial Results 26
Mar 08, 2017: Flex Pharma Reports Year End 2016 Financial Results 28
Corporate Communications 30
Oct 31, 2017: Flex Pharma Names Dr. Roger Tung to Its Board of Directors 30
Jul 31, 2017: Flex Pharma Names William McVicar President and Chief Executive Officer 31
Jun 05, 2017: Flex Pharma Announces Executive Leadership Transition 32
Apr 05, 2017: Flex Pharma appoints president of R&D 33
Legal and Regulatory 34
Aug 15, 2018: Bragar Eagel & Squire Investors That Class Action Lawsuits Have Been Filed Against Flex Pharma, Newell, and PolarityTE and Encourages Investors to Contact the Firm 34
Product News 35
04/19/2017: Flex Pharma Presents Human Efficacy Data on FLX-787 at the American Academy of Neurology Annual Meeting 35
04/05/2017: Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development 36
Clinical Trials 37
Jun 02, 2017: Flex Pharmas Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited Neuropathies Consortium 37
Apr 26, 2017: FDA Clears Flex Pharmas FLX-787 to Commence US Phase 2 Trial in ALS Under IND 38
Jan 24, 2017: Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Flex Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Flex Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Flex Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Flex Pharma Raises USD40 Million in Venture Financing 10
Flex Pharma Raises USD16 Million in Venture Financing 12
Flex Pharma Raises USD86.4 Million in IPO 13
Flex Pharma Inc, Key Competitors 15
Flex Pharma Inc, Key Employees 16

List of Figures
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Flex Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Flex Pharma Inc (FLKS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Piraeus Bank SA:企業のM&A・事業提携・投資動向
    Piraeus Bank SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Piraeus Bank SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Qvella Corp:医療機器:M&Aディール及び事業提携情報
    Summary Qvella Corp (Qvella) is a molecular diagnostics company which develops differentiated technology for rapid detection of pathogens causing Sepsis by direct sampling of bodily fluids. Its Field Activated Sample Treatment (FAST) -ID technology utilizes a novel electrical lysing and sample treat …
  • Asahi Kasei Corp (3407)-医療機器分野:企業M&A・提携分析
    Summary Asahi Kasei Corp (Asahi Kasei), formerly Asahi Chemical Industry Co. Ltd., manufactures, processes, and sells chemical products. It is a holding company of Asahi Kasei Group. The product portfolio of the company includes polymers, acrylonitrile, styrene, diagnostic reagents, foam insulation …
  • Willis Towers Watson Public Ltd Co:戦略・SWOT・企業財務分析
    Willis Towers Watson Public Ltd Co - Strategy, SWOT and Corporate Finance Report Summary Willis Towers Watson Public Ltd Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Adecco Group AG :企業の戦略・SWOT・財務情報
    Adecco Group AG - Strategy, SWOT and Corporate Finance Report Summary Adecco Group AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Phoenix Brands LLC:企業の戦略・SWOT・財務情報
    Phoenix Brands LLC - Strategy, SWOT and Corporate Finance Report Summary Phoenix Brands LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • PHOENIX Group:企業の戦略・SWOT・財務分析
    PHOENIX Group - Strategy, SWOT and Corporate Finance Report Summary PHOENIX Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Cordis Corp-医療機器分野:企業M&A・提携分析
    Summary Cordis Corporation (Cordis), a subsidiary of a Cardinal Health Inc., develops and manufactures interventional vascular products in the area of cardiology as well as for use in endovascular surgery. The company’s cardiology portfolio comprises sheaths, diagnostic guidewires, diagnostic cathet …
  • Angelo Iafrate Construction Co:企業の戦略・SWOT・財務情報
    Angelo Iafrate Construction Co - Strategy, SWOT and Corporate Finance Report Summary Angelo Iafrate Construction Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • The Mauritius Commercial Bank Limited:企業の戦略・SWOT・財務分析
    The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report Summary The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Kalle GmbH:企業の戦略的SWOT分析
    Kalle GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Nevada Gold & Casinos, Inc.:企業の戦略・SWOT・財務分析
    Nevada Gold & Casinos, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nevada Gold & Casinos, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Senzime AB (SEZI)-製薬・医療分野:企業M&A・提携分析
    Summary Senzime AB (Senzime) is a medical device company that develops patient-oriented monitoring systems. The company's product include TetraGraph monitor, CliniSenz analyzer, and Onzurf probe. Its TetraGraph monitor stimulates, measures, analyzes and displays muscle function in surgical patients …
  • Sypris Solutions Inc (SYPR):企業の財務・戦略的SWOT分析
    Sypris Solutions Inc (SYPR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Enzo Clinical Labs Inc-医療機器分野:企業M&A・提携分析
    Summary Enzo Clinical Labs Inc (Enzo Clinical), a subsidiary of Enzo Biochem Inc is a medical laboratory that offers testing services. The laboratory develops technologies in the areas of gene regulation and gene modification, biomedical and pharmaceutical research markets. It offers physicians seve …
  • CritiTech Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CritiTech Inc (CritiTech) is a pharmaceutical contract development manufacturing organization that specializes in particle engineering, material characterization, analytical testing, early stage drug development, pre-clinical and clinical manufacturing. The company uses Spray Drying and Supe …
  • Canon Machinery Inc:企業の戦略的SWOT分析
    Canon Machinery Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Cell Therapy Catapult Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Cell Therapy Catapult Ltd (Catapult) is a provider of cell and gene therapy life cycle solutions. The company offers services such as industrialization, manufacturing, regulatory, health economics and market access, non-clinical safety and clinical operations. Its health economics and market …
  • Collagen Solutions Plc (COS)-医療機器分野:企業M&A・提携分析
    Summary Collagen Solutions Plc (Collagen Solutions), formerly Healthcare Investment Opportunities Plc is a medical device company that develops, manufactures and supplies medical grade collagen biomaterials and components. The company offers sourcing and supply of high grade collagen; provision of f …
  • Mabuhay Vinyl Corp (MVC):企業の財務・戦略的SWOT分析
    Mabuhay Vinyl Corp (MVC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆